The limitations of clinical traits (including AJCC stage, Furman score, and pathological grade) and emerging molecular alterations (e.g., VHL, PBRM1 mutation, microsatellite stage, and tumor mutation burden) hinder the capacity to provide optimal clinical management to ccRCC patients [48]. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.